 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Capricor Therapeutics Inc (NASDAQ:CAPR - Get Free Report) saw a large increase in short interest in the month of March. As of March 15th, there was short interest totalling 3,230,000 shares, an...

Short Interest in Capricor Therapeutics Inc (NASDAQ:CAPR) Grows By 19.6%

This is a signal that CAPR's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...

Capricor Therapeutics (CAPR, $6.31) RSI Indicator left the overbought zone on March 26, 2024

Capricor Therapeutics (CAPR, $6.63) RSI Indicator left the overbought zone on March 25, 2024

SAN DIEGO, March 21, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and...

Capricor Therapeutics to Present at Upcoming Investor Conferences

Capricor Therapeutics Inc (NASDAQ:CAPR  Free Report)  Stock analysts at Cantor Fitzgerald issued their FY2024 earnings per share (EPS) estimates for shares of Capricor Therapeutics in...

Capricor Therapeutics Inc to Post FY2024 Earnings of ($0.84) Per Share, Cantor Fitzgerald Forecasts (NASDAQ:CAPR)

CAPR's total volume now sits at 926.7K. The +0.44% price change was insignificant, leaving IBM's price at $6.79...

The volume for Capricor Therapeutics stock increased for one day, resulting in a record-breaking daily growth of 249% of the 65-Day Volume Moving Average

This price move could be a signal that CAPR may fall back below the higher band and head toward the middle band. Traders may consider selling the stock, shorting the stock, or exploring put options...

Capricor Therapeutics (CAPR, $5.87) price may drop as it broke higher Bollinger Band on Mar 08, 2024

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Capricor Therapeutics presents results from HOPE-2 extension study

Presentation Highlights Positive 24-Month Results from HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular DystrophySAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- Capricor...

Capricor Therapeutics Presents at 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

It is a pleasure to report that the Capricor Therapeutics, Inc. ( NASDAQ:CAPR ) is up 38% in the last quarter. But that...

Capricor Therapeutics (NASDAQ:CAPR) adds US$19m to market cap in the past 7 days, though investors from three years ago are still down 11%

Capricor Therapeutics, Inc. engages in the discovery, development and commercialization of biological therapies for the treatment of cardiac and other serious medical conditions. Its product candidate consists of CAP-1002, Cenderitide, Exosomes, CAP-1001, CU-NP and CSps. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Volume (M)	221,307.00
52-Wk High	$8.22
52-Wk Low	$2.68

Current Price	$5.92
Prev Close	$5.86
Open	$5.77
Dividend Yield	0.00%
50-Day Moving Average	$5.35
Beta	0.80
Avg. Volume	423,812.70
PE Ratio	-6.73

52-Week High	$8.22
52-Week Low	$2.68
Market Capitalization	$184.61M
EPS	-$0.8708
Price to Book	8.08
Revenue Per Employee	$246,843.78
Enterprise Value/EBITDA	-5.09

CAPR Capricor Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals